Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease

Neurobiol Dis. 2001 Jun;8(3):433-46. doi: 10.1006/nbdi.2001.0388.

Abstract

Neurodegenerative diseases represent promising targets for gene therapy approaches provided effective transfer vectors. In the present study, we evaluated the effectiveness of LacZ-expressing lentiviral vectors with two different internal promoters, the mouse phosphoglycerate kinase 1 (PGK) and cytomegalovirus (CMV), to infect striatal cells. The intrastriatal injection of lenti-beta-Gal vectors lead to 207, 400 +/- 11,500 and 303,100 +/- 4,300 infected cells in adult rats, respectively. Importantly, the beta-galactosidase activity was higher in striatal extracts from PGK-LacZ-injected animals as compared to CMV-LacZ animals. The efficacy of the system was further examined with a potential therapeutic gene for the treatment of Huntington's disease, the human ciliary neurotrophic factor (CNTF). PGK-LacZ- or PGK-CNTF-expressing viruses were stereotaxically injected into the striatum of rats, 3 weeks later the animals were unilaterally lesioned with 180 nmol of quinolinic acid (QA). Control animals displayed 148 +/- 43 apomorphine-induced rotations ipsilateral to the lesion 5 days postlesion as compared to 26 +/- 22 turns/45 min in the CNTF-treated group. The extent of the striatal damage was significantly diminished in the CNTF-treated rats as indicated by the 52 +/- 9.7% decrease of the lesion volume and the sparing of DARPP-32, ChAT and NADPH-d neuronal populations. These results further establish that lentiviruses may represent an efficient gene delivery system for the screening of therapeutic molecules in Huntington's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ciliary Neurotrophic Factor / genetics*
  • Cytomegalovirus / genetics
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Genetic Therapy / methods*
  • Genetic Vectors*
  • Huntington Disease / chemically induced
  • Huntington Disease / therapy*
  • Lentivirus / genetics*
  • Neuroprotective Agents
  • Phosphoglycerate Kinase / genetics
  • Promoter Regions, Genetic
  • Quinolinic Acid
  • Rats
  • Rats, Wistar
  • beta-Galactosidase / genetics

Substances

  • Ciliary Neurotrophic Factor
  • Neuroprotective Agents
  • Phosphoglycerate Kinase
  • beta-Galactosidase
  • Quinolinic Acid